Home / People / Jean-Baptiste Thiénot
Portrait ofJean-Baptiste Thiénot

Jean-Baptiste Thiénot

Partner

Contact
CMS Francis Lefebvre Avocats
2 rue Ancelle
92522 Neuilly-sur-Seine
Cedex
France
Languages French, English, German

Jean-Baptiste Thiénot is Partner in the IP/IT team of CMS Francis Lefebvre. He mainly advises on industrial property law, particularly patent law.

His activity covers litigation (infringement and nullity actions, employee invention issues) as well as advice and drafting of contracts (R&D contracts, assignment and licensing, audit of rights portfolio) in various industrial sectors, particularly in the life sciences, mechanical and electronic fields. He is frequently involved in cases relating to products subject to specific regulations (health products, cosmetics, spraying, etc.).

Jean-Baptiste has also developed a particular expertise in the protection of business secrets/know-how (litigation, implementation of internal protection policies) and the regulation of health products (medicines, medical devices, etc.). He advises manufacturers in the health sector on their innovative projects, particularly in relation to e-health (telemedicine) and the compliance of their practices ("anti-gift" and "transparency" laws).

Jean-Baptiste Thiénot has been a lawyer since 2008. He joined CMS Francis Lefebvre in 2018 after practising with the law firms Simmons & Simmons (2008-2011), Allen & Overy (2011-2013) and Bird & Bird (2013-2018).

more less

Intellectual propety : patents

Legal 500 EMEA 2023

Memberships & Roles

  • Member of LES, APRAM and AIPPI
  • Member of Carré des juristes de France Biotech
  • Member of Bar Hauts-de-Seine
more less

Publications

  • « Secondes applications thérapeutiques : la décision « SANTEN » rebat les cartes »- La Lettre PI (february 2021)
  • « Action en nullité de brevet : la démonstration de l’intérêt à agir » - La Lettre PI (january 2021)
  • « Mouvements de salariés et protection des informations confidentielles de l’entreprise » - La lettre des fusions acquisitions et du private equity (Option Finance) (december 2020)
  • « Dernières actualités concernant le dispositif « anti-cadeaux »» - LinkedIn (november 2020)
  • « MSD’s ezetimibe-simvastatin SCP revoked by the Paris Court of Appeal » - The SPC Blog (october 2020)
  • « Réforme anti-cadeaux : quelles actions mettre en place ? » - LinkedIn (september 2020)
  • « Vers une responsabilité accrue des plateformes numériques dans la lutte contre la contrefaçon ? » - La Lettre PI (april 2020)
  • Propriété intellectuelle et opération de fusion acquisition : préférez une revue sur mesure » - La lettre des fusions acquisitions et du private equity - Option Finance (march 2020)
  • « Le renouveau des interdictions provisoires (preliminary injunctions) » – Bulletin rapide de droit des affaires (BRDA) (march 2020)
  • Recent changes in patent law” - LinkedIn (march 2020)
more less

Education

  • Master II « droit de la propriété littéraire et artistique », Université Paris II–Assas dirigé par Pierre-Yves Gautier (2005)
  • CAPA (2008)
more less

Feed

04/04/2024
France: A public consultation on Digital Medical Devices for mental health
March 2024
27/03/2024
Cannabis law and legislation in France
Medical use In principle, pursuant to Article R. 5132-86 of the French Public Health Code (PHC), the culture, manufacture, transport, import, export, holding, offer, transfer, acquisition and use of cannabis...
01/02/2024
Early days of the UPC - key issues and take-aways
 
18/12/2023
Digital health apps and telemedicine in France
Digital Health Apps/Software 1. How is the software within digital health apps classified in your jurisdiction, and what regulation(s) apply? 1.1 Is it considered a “medical device” or a “product”...
Comparable
21/07/2023
CMS International Patent Litigation Guide
Patented technology often ranks among a company's most valued as­sets. Pro­tect­ing your business from patent in­fringe­ment – or defending yourself against patent infringement claims of third parties – can be a complex and intensive process. CMS International Patent Litigation Guide (4th edition) is your essential tool to get an overview of the options and pathways to enforce patents in the courts of 18 major jurisdictions. Drawing on the expertise of CMS patent law specialists, this essential and fully-updated guide provides clear and concise coverage of patent infringement proceedings and practice. For each jurisdiction, you can quickly assess and compare critical issues such as:Standing - Who is entitled to sue for patent infringement, the number of parties that can be included in proceedings and time limits in which infringement claims must be boughtTiming and Forum – Where proceedings are brought, typical duration of trials and the handling of FRAND/compulsory licenses in court pro­ceed­ing­sEvid­ence – Use of expert witnesses, disclosure requirements and rules on seizure of evid­ence/doc­u­ment­s­Ap­peals – Routes, grounds and timings for appeal – and the potential interim enforcement of first instance de­cisionsCosts – Estimated legal costs, appeal costs and recoverability of litigation costsIn addition, the CMS International Patent Litigation Guide covers topics like Alternative Dispute Resolution, Remedies and Injunctions – and your CMS Patent Law team in each market. For dedicated information on the enforcement of European Patents before the Unified Patent Court please also visit our CMS UPC Insight  webpage.
13/04/2023
LEGAL 500 EMEA 2023
The 2023 edition of the Legal 500 EMEA guide is out. We would particularly like to thank our clients for putting their trust in us! Our law firm’s rankings in France France 2 in Tier 1 : Derivatives...
29/09/2022
Global LSHC Forum 2022
Uncertain times, an evolving legal framework: managing risks and ensuring social responsibility in the life sciences & healthcare sector
15/09/2022
Pharmaceutical advertising regulation and medical device advertising in...
Rules applicable to the advertising of veterinary medicines are not addressed in this questionnaire. 1. Which laws are applicable regarding advertising of medicines and medical devices? 1.1 Medicines...
26/07/2022
European Bolar Provisions in France
1. How is Bolar implemented? The EU Directives  were implemented at the French national level through the Law n°2007-248 of February 26th, 2007 containing various provisions for adapting to Community...
Comparable
07/06/2022
Adverse effects of drugs and vaccines in France
1. Drug adverse effects: kinds of responsibility 1.1 Which are the main kinds of responsibility (contractual, in tort, criminal) of the following subjects with respect to adverse drugs reactions? A. ...
Comparable
07/06/2022
Trade secret laws and regulations in France
General 1. Has the Directive (EU) 2016/943 of the European Parliament and of the Council of 8 June 2016 on the protection of undisclosed know-how and business information (trade secrets) against their...
Comparable
13/04/2022
LEGAL 500 EMEA 2022
The 2022 edition of the Legal 500 EMEA guide is out. We would particularly like to thank our clients for putting their trust in us! Our law firm’s rankings in France, Algeria and Morocco France...